Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How One China State-Owned Group Became A Behemoth, Powered By COVID-19

But Will Size, Speed, Policy Support Matter More Than Innovation?

Executive Summary

Already producing a broader range of biologics than any biotech firm in the world, from antibodies via plasma products to testing assays to vaccines, the state-owned China National Biotec Group is becoming even bigger with policy support and one surprising helper: the coronavirus pandemic. But might it face challenges from innovators and foreign firms in a changing environment?

You may also be interested in...



As US, China Intensify Cybersecurity Crackdown, Companies Urged To Be Conservative

The latest developments around data security and protection signal the need for rigorous implementation of procedures and potential significant cost increases for pharma and other companies operating in China.

Fosun-BioNTech mRNA Vaccine Nears China Green Light

There is talk about offering booster shots to people who have already been fully vaccinated against COVID-19 in China and it’s increasingly clear that the mRNA vaccine from BioNTech/Fosun nearing approval could be the answer. Meanwhile, some Asian countries are turning away from Chinese coronavirus vaccines. 

Biogen Partners With InnoCare To Keep Up With BTK Inhibitor Leaders in MS

BTK Inhibitors could be a major advance multiple sclerosis therapy, and Biogen has bought into a potential challenger to Phase III frontrunner from Sanofi and Roche.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel